

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

KPC3

RRID:CVCL_A9ZK

Type: Cell Line

Proper Citation

RRID:CVCL_A9ZK

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A9ZK

Proper Citation: RRID:CVCL_A9ZK

Description: Cell line KPC3 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse pancreatic neoplasm

Defining Citation: [PMID:30381448](#), [PMID:32690771](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: KPC3

Cross References: Wikidata:Q102114430

ID: CVCL_A9ZK

Record Creation Time: 20220427T220708+0000

Record Last Update: 20260829T234427+0000

Ratings and Alerts

No rating or validation information has been found for KPC3.

No alerts have been found for KPC3.

Data and Source Information

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Horvathova L, et al. (2025) Alphavirus replicons encoding IFN- γ enhance cancer virotherapy by overcoming macrophage-mediated suppression. *iScience*, 28(10), 113545.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. *Cancer cell*, 42(6), 1032.

Groeneveldt C, et al. (2024) Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. *Cancer immunology research*, 12(3), 334.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. *Cell reports*, 42(12), 113516.

Groeneveldt C, et al. (2023) Intertumoral Differences Dictate the Outcome of TGF- β Blockade on the Efficacy of Viro-Immunotherapy. *Cancer research communications*, 3(2), 325.

Boelaars K, et al. (2023) Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. *Journal for immunotherapy of cancer*, 11(11).

Borst L, et al. (2022) NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division. *International journal of cancer*, 150(4), 688.